Medical News

RSS

Nation-wide study to assess risk of suicide among men

The introduction of prostate-specific antigen (PSA) testing as a screening tool for early detection of prostate cancer (PCa) in the beginning of the 1990s drastically increased the detection of PCa. The risk of suicide is increased among cancer patients including men with PCa.

23 Feb 2010

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.

23 Feb 2010

LFB Biotechnologies provides new loan financing to GTC Biotherapeutics for key strategic programs

GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) announced that it has entered into an agreement with its strategic partner, LFB Biotechnologies (Les Ulis, France), pursuant to which LFB has agreed to provide $7 million of new loan financing to GTC.

23 Feb 2010

KHN column - Malpractice Reform: A test case for bipartisanship at the health summit

In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Ever since President Barack Obama announced he'd be having a bipartisan meeting to talk about health care reform, Republicans have been denouncing it as a charade.

23 Feb 2010

Senate, FDA reports increasing concerns about controversial diabetes drug

"Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market ... ," The New York Times reports. "The internal F.D.A. reports are part of a fierce debate within the agency over what to do about Avandia, manufactured by GlaxoSmithKline."

23 Feb 2010

DSAEK cornea transplant offers potential long-term benefits

One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty experienced greater cell loss overall compared to those who underwent penetrating keratoplasty, according to a new analysis of data collected from the Cornea Donor Study Investigator Group's 2008 Specular Microscopy Ancillary Study.

23 Feb 2010

AAAS meeting examines test-and-treat model's potential for fighting HIV spread, TB co-infection

Researchers speaking at the American Association for the Advancement of Science (AAAS) meeting on Saturday, discussed how a strategy to promote universal voluntary HIV tests and early antiretroviral treatment for patients living in high-risk areas might "derail the spread of [HIV/]AIDS, a battle where a successful vaccine remains elusive," the Associated Press/Washington Post reports

23 Feb 2010

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss.

23 Feb 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

Enzymerx completes enrollment for clinical trial of pegsitacase

EnzymeRx, LLC, a clinical-stage biotechnology company, announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

22 Feb 2010

Researchers measure diffusion coefficient of a protein in a primary cilium

A team of researchers led by Peter Calvert (SUNY Upstate Medical University) has, for the first time, measured the diffusion coefficient of a protein in a primary cilium and in other major compartments of a highly polarized cell. The study appears in the March issue of the Journal of General Physiology.

22 Feb 2010

Maine studies prospects for state reform efforts while N.Y. experience shows impact of guaranteeing access to coverage

In Maine, insurance regulators say measures aimed at expanding health coverage to more people in that state should wait for final action in Congress, The Associated Press/WBZ reports. A Maine report "released last week, stems from a 2009 law that asks the superintendent to review ways to improve the availability and affordability of Maine's individual health insurance market." In the report, the authors write that Maine's options to expand access and make coverage more affordable will depend on what Congress does.

22 Feb 2010

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Chiltern International Limited, a global contract research organization (CRO), announced its latest collaboration with Charles River Laboratories, Inc. As part of this collaboration, Chiltern Early Phase will partner with Charles River to conduct and support early phase radiolabelled studies.

22 Feb 2010

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Ritter Pharmaceuticals, a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24.

22 Feb 2010

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced that its CM-AT autism treatment, now in Phase III clinical trials, has been designated as a Fast Track drug by the U.S. Food and Drug Administration (FDA).

22 Feb 2010

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund’s capital is from returning investors, and the fund’s partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

22 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

Obama's health plan to target insurers' rates

President Obama will propose a regulatory crack down on insurers' rate hikes this morning, as the administration seeks to set the stage for a week-long push to reinvigorate the health care debate, The New York Times reports.

22 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Researchers at the University of Illinois at Chicago Institute for Health Research and Policy have received a $2.2 million federal grant to determine whether or not TV food advertising affects children's diet, physical activity and weight.

22 Feb 2010

Medical News

Nation-wide study to assess risk of suicide among men

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

LFB Biotechnologies provides new loan financing to GTC Biotherapeutics for key strategic programs

KHN column - Malpractice Reform: A test case for bipartisanship at the health summit

Senate, FDA reports increasing concerns about controversial diabetes drug

DSAEK cornea transplant offers potential long-term benefits

AAAS meeting examines test-and-treat model's potential for fighting HIV spread, TB co-infection

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

Enzymerx completes enrollment for clinical trial of pegsitacase

Researchers measure diffusion coefficient of a protein in a primary cilium

Maine studies prospects for state reform efforts while N.Y. experience shows impact of guaranteeing access to coverage

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

Obama's health plan to target insurers' rates

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News